Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Third Wave s PGx Test for Camptosar Adverse Events

NEW YORK, Aug. 24 (GenomeWeb News) - Third Wave this week received approval from the US Food and Drug Administration for a pharmacogenetic test that takes advantage of the recent re-labeling of a lucrative chemotherapy drug.

 

Third Wave claimed that its test is "the first pharmacogenetic test to be approved by the FDA for use as a companion diagnostic to a specific drug therapy," in a statement.

 

According to Third Wave, the FDA has cleared its Invader UGT1A1 molecular assay for use in identifying patients who may be at increased risk of adverse reaction to Pfizer's Camptosar, a chemotherapy drug for colorectal cancer.

 

The assay detects and identifies mutations in the UGT1A1 gene associated with that risk, and takes advantage of a recent re-labeling of Camptosar, which now includes dosing recommendation based on the patient's genetic profile.

 

Camptosar brought Pfizer first-quarter 2004 revenue of $212 million, up 132 percent compared to the same period in 2004, according to a statement from Pfizer. Sales in the United States account for about half of the drug's worldwide sales, Pfizer said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.